To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Podcast: Listen
Michigan Chronicle About 90% of liver cancer cases are hepatocellular carcinoma (HCC). The Michigan Chronicle looks at how more African Americans are diagnosed with liver cancer than White Americans. The new TheraBionic P1 medical device that Karmanos will offer patients in 2024 is FDA approved to treat this advanced-stage liver cancer after patients have failed first- and second-line treatment options. Boris Pasche, M.D., Ph.D., FACP , president and CEO at Karmanos, and Anthony Shields, M.D., Ph.D. , m...
The Barbara Ann Karmanos Cancer Institute , along with cancer centers and other organizations across the nation, recognizes November as Pancreatic Cancer Awareness Month. As its name indicates, pancreatic cancer originates in the pancreas, an organ that sits behind the stomach. The pancreas aids in digestion and helps regulate blood sugar. About Pancreatic Cancer Exocrine cells make up the majority of the pancreas. When these cells grow out of control, adenocarcinoma of the pancreas occurs. Pancreatic a...
DBusiness Karmanos Cancer Institute in Detroit will be the first provider to offer the TheraBionic P1 medical device for the treatment of advanced hepatocellular carcinoma, the most common type of liver cancer. Boris Pasche, M.D., Ph.D., FACP , president and CEO at Karmanos, and Anthony Shields, M.D., Ph.D. , medical oncologist and leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team , explain the device's benefits to patients 18 years and older who have failed first- ...
In this episode, Dr. Anthony Shields, associate center director for Clinical Sciences for Karmanos Cancer Institute and professor of Medicine and Oncology at Wayne State University School of Medicine, discusses biomarker testing.